PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.50%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-488.33%
Other expenses reduction while AGEN shows 0.00% growth. Joel Greenblatt would examine efficiency.
-14.77%
Operating expenses reduction while AGEN shows 9.23% growth. Joel Greenblatt would examine advantage.
-14.77%
Total costs reduction while AGEN shows 7.94% growth. Joel Greenblatt would examine advantage.
-25.91%
Both companies reducing interest expense. Martin Whitman would check industry trends.
18928.57%
D&A growth while AGEN reduces D&A. John Neff would investigate differences.
439.10%
EBITDA growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
10.94%
Operating income growth while AGEN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
70.03%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-47.20%
Both companies reducing tax expense. Martin Whitman would check patterns.
11.95%
Net income growth below 50% of AGEN's 57.67%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
11.92%
EPS growth below 50% of AGEN's 62.86%. Michael Burry would check for structural issues.
11.92%
Diluted EPS growth below 50% of AGEN's 62.86%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.